文献速递慢性肾脏病水电解质与酸碱

老年CKD患者别嘌醇起始剂量与严重皮肤反应风险:基于人群的队列研究

Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2022-05-27

该研究利用加拿大安大略省2008至2019年链接医疗数据库,纳入47315例66岁以上、eGFR<60 mL/min/1.73 m2的别嘌醇新使用者,比较起始剂量>100 mg/d与≤100 mg/d。结果显示,>100 mg/d组在180天内因严重皮肤反应就诊的加权风险为0.40%,≤100 mg/d组为0.18%,加权RR为2.25(95% CI 1.50-3.37),加权RD为0.22%(95% CI 0.12%-0.32%),全因住院风险增加但全因死亡无差异。

要点

  • 老年CKD患者起始别嘌醇>100 mg/d较≤100 mg/d,180天内严重皮肤反应加权风险升高,加权RR 2.25(95% CI 1.50-3.37)。
  • 加权严重皮肤反应事件数:>100 mg/d组103/25802(0.40%) vs ≤100 mg/d组46/25816(0.18%)。
  • 起始别嘌醇>100 mg/d与全因住院风险增加相关,但与全因死亡无显著关联。

核心结论

  • 老年CKD患者起始别嘌醇>100 mg/d较≤100 mg/d,180天内因严重皮肤反应就诊的风险约为后者的2倍。

研究设计与样本

  • 基于人群的队列研究,使用链接医疗数据库,纳入加拿大安大略省2008至2019年66岁以上、eGFR<60 mL/min/1.73 m2的别嘌醇新使用者47315例。

主要发现

  • 起始别嘌醇>100 mg/d组加权严重皮肤反应事件数为103/25802(0.40%),≤100 mg/d组为46/25816(0.18%)。
  • 起始别嘌醇>100 mg/d较≤100 mg/d的加权RR为2.25(95% CI 1.50-3.37),加权RD为0.22%(95% CI 0.12%-0.32%)。
  • 起始别嘌醇>100 mg/d与全因住院风险增加相关,但与全因死亡无显著关联。

局限性

  • 该研究检验效能不足,无法检测不同eGFR类别(即45-59、30-44和<30 mL/min/1.73 m2)下别嘌醇剂量与结局关联的风险差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Allopurinol should be started at lower doses in patients with chronic kidney disease (CKD) to avoid adverse effects. We examined the risk of severe cutaneous reactions in older adults with CKD who were newly prescribed allopurinol at varied doses. STUDY DESIGN: Population-based cohort study using linked health care databases. SETTING & PARTICIPANTS: Patients in Ontario, Canada (2008-2019) aged ≥66 years, with an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2, and who were new users of allopurinol. EXPOSURE: A new prescription for allopurinol >100 mg/d versus a dose ≤100 mg/d. OUTCOME: The primary outcome was a hospital visit with a severe cutaneous reaction within 180 days of starting allopurinol. Secondary outcomes included all-cause hospitalization and all-cause mortality. ANALYTICAL APPROACH: The exposure and referent groups were balanced on indicators of baseline health using inverse probability of treatment weighting on the propensity score. Weighted risk ratios (RR) were obtained using modified Poisson regression and weighted risk differences (RD) using binomial regression. RESULTS: Of 47,315 patients (median age, 76 years; median eGFR, 45 mL/min/1.73 m2), 55% started allopurinol at >100 mg/d. Starting allopurinol at >100 versus ≤100 mg/d was associated with an increased risk of a severe cutaneous reaction: number of events (weighted), 103 of 25,802 (0.40%) versus 46 of 25,816 (0.18%), respectively (weighted RR, 2.25 [95% CI, 1.50-3.37]; weighted RD, 0.22% [95% CI, 0.12%-0.32%]. Starting allopurinol at >100 versus ≤100 mg/d was associated with an increased risk of all-cause hospitalization but not with all-cause mortality. LIMITATIONS: This study was underpowered to detect risk differences in the association of allopurinol dose with outcomes across eGFR categories (ie, 45-59, 30-44, and <30 mL/min/1.73 m2). CONCLUSIONS: Older patients with CKD who started allopurinol at >100 mg/d versus ≤100 mg/d were twice as likely to visit a hospital with a severe cutaneous reaction in the next 180 days.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Bathini L, Garg AX, Sontrop JM, et al. Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2022. PMID: 35644439. doi:10.1053/j.ajkd.2022.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。